Dapagliflozin, a selective inhibitor of SGLT2, could reduce right ventricle systolic pressure and attenuate pulmonary vascular remodelling in MCT-induced PAH, which was in accord with the results of empagliflozin in MCT-induced PAH [14]. The gene discussed is SLC5A2; the disease is pulmonary arterial hypertension.